Publikationen in Zusammenarbeit mit Forschern von King's College London (145)

2024

  1. AI is a viable alternative to high throughput screening: a 318-target study

    Scientific Reports, Vol. 14, Núm. 1

  2. Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis

    Schizophrenia bulletin, Vol. 50, Núm. 3, pp. 496-512

  3. Cognitive remediation therapy to enhance cognition and improve recovery in early psychosis: the ECLIPSE research programme including an RCT

    Programme Grants for Applied Research, Vol. 12, Núm. 4

  4. Correction to: AI is a viable alternative to high throughput screening: a 318-target study (Scientific Reports, (2024), 14, 1, (7526), 10.1038/s41598-024-54655-z)

    Scientific Reports

  5. Data-driven, harmonised classification system for myelodysplastic syndromes: a consensus paper from the International Consortium for Myelodysplastic Syndromes

    The Lancet Haematology, Vol. 11, Núm. 11, pp. e862-e872

  6. Development of the PSYCHS: Positive SYmptoms and Diagnostic Criteria for the CAARMS Harmonized with the SIPS

    Early Intervention in Psychiatry, Vol. 18, Núm. 4, pp. 255-272

  7. Effects of cannabidiol on symptoms in people at clinical high risk for psychosis

    World Psychiatry

  8. Identifying tinnitus in mice by tracking the motion of body markers in response to an acoustic startle

    Frontiers in Neuroscience, Vol. 18

  9. Implementation of community screening strategies for depression

    Nature Medicine

  10. Increased hippocampal blood flow in people at clinical high risk for psychosis and effects of cannabidiol

    Psychological Medicine, Vol. 54, Núm. 5, pp. 993-1003

  11. International Headache Society Global Practice Recommendations for Preventive Pharmacological Treatment of Migraine

    Cephalalgia : an international journal of headache, Vol. 44, Núm. 9

  12. International Headache Society global practice recommendations for the acute pharmacological treatment of migraine

    Cephalalgia : an international journal of headache, Vol. 44, Núm. 8

  13. LocoMMotion: a study of real-life current standards of care in triple-class exposed patients with relapsed/refractory multiple myeloma – 2-year follow-up (final analysis)

    Leukemia

  14. Prevalence and characteristics of visual snow syndrome in a cohort of young Italian adults

    European Journal of Neurology

  15. Training in neuropsychiatry: views of early career psychiatrists from across the world

    BJPsych Bulletin, Vol. 48, Núm. 2, pp. 78-84

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS-Flow Cytometry Working Group

    Cytometry Part B - Clinical Cytometry, Vol. 104, Núm. 1, pp. 77-86

  3. Cognitive Remediation Works But How Should We Provide It? An Adaptive Randomized Controlled Trial of Delivery Methods Using a Patient Nominated Recovery Outcome in First-Episode Participants

    Schizophrenia bulletin, Vol. 49, Núm. 3, pp. 614-625

  4. Consensus Clinical Guidance for Diagnosis and Management of Adult COVID-19 Encephalopathy Patients

    Journal of Neuropsychiatry and Clinical Neurosciences, Vol. 35, Núm. 1, pp. 12-27

  5. Corrigendum to “Global uncertainty in the diagnosis of neurological complications of SARS-CoV-2 infection by both neurologists and non-neurologists: An international inter-observer variability study” [Journal of the Neurological Sciences. 2023 Jun 15;449:120646] (Journal of the Neurological Sciences (2023) 449, (S0022510X23001065), (10.1016/j.jns.2023.120646))

    Journal of the Neurological Sciences